
Mendus Q1 2023 - Opportunities and hurdles

Redeye provides its comment on Mendus' Q1 2023 report. We believe the company has a solid plan for continued clinical development of vididencel and ilixadencel. However, uncertainties around financing these trials cast a shadow over the investment case.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Mendus Q1 2023 - Opportunities and hurdles